Revolutional Therapy for Metabolic Syndrome

The First And Only Multitarget Drug Against Metabolic Syndrome And Its Related Diseases

  • One Molecule Combating Multiple Targets – Type 2 Diabetes, Organ Fibrosis, Non-Alcoholic Fatty Liver Disease, Heart Disease, And Kidney Disease
  • More Predictable Pharmacokinetics (Body Reactions) With Prolonged Duration Of Effectiveness
  • Oral Administration Prevents The Unpleasantness Of Insulin Injections And Other Complications Associated With The Existing Therapies
  • Cost Effective

About Us

Scientists at Medical College of Wisconsin and Goethe University Frankfurt have discovered RB394, a novel bifunctional molecule, to combat metabolic disorders associated organ diseases, heart disease & type 2 diabetes. MetaSyn Therapeutics is dedicated to developing the multitarget drug that leverages RB394’s potential to meaningfully improve the lives of patients affected by metabolic syndrome and its related diseases.


Metabolic Syndrome is a multifactorial disease where current available treatments require a combination of different drugs to tackle the multiple abnormalities associated with it.
This leads to:

MetaSyn Therapeutics aims at developing a multitarget drug to treat all aspects of metabolic syndrome.

Reverse Type 2 Diabetes

T2B is a major complication developed from metabolic syndrome. The novel RB394 molecule is a glucose-lowering agent with a strong ability to treat diabetic complications.

Protect the Organs

RB394 shows activity in treating organ fibrosis. It decreases renal and liver injury, as well as protects the kidney and heart.

Mitigate Kidney Disease

Chronic kidney disease can also be associated with metabolic syndrome. RB394 can reduce kidney inflammation, oxidative stress, tubular injury, and vascular injury.

Prevent Heart Disease

Heart disease is another major complication developed from metabolic syndrome. RB394 improves lipid profile and heart function. It lowers blood pressure & prevents development of hypertension.

Treat Liver Disease

RB394 treats non-alcoholic fatty liver disease (NAFLD), non-alcoholic hepatic steatosis (NASH), & is anti-inflammatory, anti-fibrotic.


  • Multi-target drugs have much more potential than single-target and highly specific agents due to better (i) disease modifying actions, (ii) additive and/or synergistic therapeutic actions, (iii) more predictable pharmacokinetics, (iv) prolonged duration of effectiveness, and (v) lower probability for drug interactions.
  • Oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.
Metabolic syndrome rats show decreased blood pressure, improved insulin action, improved lipid profile, and decreased kidney & heart injury
Type 2 diabetic rats show decreased blood pressure, decreased blood glucose, improved insulin action, decreased kidney injury, and decreased liver injury


The global metabolic disorder therapeutics market was valued at USD 57 billion in 2019 and is expected to grow at a CAGR of 7.56% to USD 89 billion in 2025. Increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Various governments and healthcare associations around the world have estimated that more than half a billion individuals are to be affected by obesity and diabetes by 2040. Also, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth.

Metabolic syndrome affects 23% of the US adult population.

Market Drivers


John D. Imig, PhD

Professor, Pharmacology and Toxicology Medical College of Wisconsin

General Interests: Cardiovascular, Obesity, Diabetes and Hypertension

PhD, Physiology and Biophysics, University of Louisville, 1990
BA, Biology, Blackburn College, 1985


The Imig laboratory is dedicated to understanding the mechanisms by which certain fatty acids “eicosanoids” influence kidney and cardiovascular function. Research in the laboratory focuses on kidney and blood vessel function in normal and disease states. The team have developed novel eicosanoid-based drugs to treat diseases including hypertension, stroke, heart attacks, diabetes, and kidney diseases. These novel drugs have tremendous potential as a therapy for cardiovascular and kidney diseases.

Eugen Proschak, PhD

Professor, Drug Design Institute of Pharmaceutical Chemistry Goethe University of Frankfurt

General Interests: Rational design of multi-target drugs, Fragment-based drug design, Design of lipid signaling modulators

Education: PhD, Goethe University of Frankfurt, Frankfurt, Germany


Eugen Proschak is a Professor for Drug Design at the Institute of Pharmaceutical Chemistry at the Goethe University of Frankfurt. After his doctoral and postdoctoral studies at the Goethe University he became Independent Group Leader at the Lipid Signaling Research Center (LIFF) in Frankfurt. He worked on hit identification and hit-to-lead optimization for fatty acid mimetics. His current research interests are design and synthesis of multi-target drugs for treatment of metabolic syndrome.

Jason Pottinger, MBA

Chief Executive Officer

Dr. Vikas Desai, MD

Chief Scientific Officer

Dr. Nick Poulios, PhD, PhM


Dr. Frank Greenway, MD


Corey Park

Strategic Advisor

Contact Us

About Us

MetaSyn Therapeutics develops breakthrough technology for treating metabolic syndrome and its related diseases.

We seek medical and/or technological partners to bring the drug to the market.